ArticleNaunyn-Schmiedeberg's archives of pharmacology2024
How do German pharmacologists publish in the non-peer-reviewed science magazine Biospektrum?
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 9 citations in OpenAlex.
- A brief history of the German Society for Experimental and Clinical Pharmacology and Toxicology-an overview of available sources.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- National-, institutional-, and individual-level determinants of pharmacology and pharmacy research excellence: an analysis of stanford-elsevier lists of the top 2% scholars (2017-2023).Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Country-specific citation disparities in Naunyn-Schmiedeberg's Archives of Pharmacology from 2001 to 2024.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- The Schmiedeberg Medal of the German Society for Experimental and Clinical Pharmacology and Toxicology: a biographical and bibliometric analysis of the 47 recipients from 1956 to 2024.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Gender- and discipline-specific bibliometric analysis of elite biomedical scientists: how is pharmacology performing?Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Arbitrariness of bibliometric parameters: a case study on leading scientists in the German Society for Experimental and Clinical Pharmacology and Toxicology (DGPT).Naunyn-Schmiedeberg's archives of pharmacology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Publications in peer-reviewed journals are the most important currency in science. But what about publications in non-peer-reviewed magazines? The objective of this study was to analyze the publications of scientists, with a focus on pharmacologists, in the non-peer-reviewed German science magazine Biospektrum from 1999 to 2021. Biospektrum is edited by five scientific societies in Germany including the Society for Experimental and Clinical Society Pharmacology and Toxicology (DGPT) and provides opportunities to researchers to showcase their research to a broad audience. We analyzed 3197 authors of 1326 articles. Compared to the fields of biochemistry, microbiology, and genetics, pharmacology was largely underrepresented. Just three institutions in Germany contributed most papers to Biospektrum. Researchers with a doctoral degree were the largest author group, followed by researchers with a habilitation degree. Among all major fields, women were underrepresented as authors, particularly as senior authors. The Covid pandemic leads to a drop of publications of female first authors but not last authors. Compared to publications in the peer-reviewed journal Naunyn-Schmiedeberg's Archives of Pharmacology (Zehetbauer et al., Naunyn-Schmiedebergs Arch Pharmacol 395:39-50 (2022)), female pharmacologists were underrepresented in the Biospektrum. Thus, German pharmacologists as a group do not value investing in "social impact" gained by publications in Biospektrum, and this attitude is even more prominent among female pharmacologists. Investing less in "social impact" by female pharmacologists may result in reduced visibility on the academic job market and may contribute to reduced opportunities to achieve high academic positions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.